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Abstract 
A European Society for Medical Oncology (ESMO)-sponsored expert meeting was held in Paris on 08 
March 2018 which comprised 11 experts from academia, 11 experts from the pharmaceutical industry 
and two clinicians who were representatives of ESMO. The focus of the meeting was exclusively on 
the intratumoral injection/delivery of immunostimulatory agents with the aim of harmonizing the 
standard terms and methodologies used in the reporting of human intratumoral immunotherapy (HIT-
IT) clinical trials to ensure quality assurance and avoid a blurring of the data reported from different 
studies. The goal was to provide a reference document, endorsed by the panel members, that could 
provide guidance to clinical investigators, pharmaceutical companies, ethics committees, independent 
review boards, patient advocates and the regulatory authorities, and promote an increase in the 
number and quality of HIT-IT clinical trials in the future. Particular emphasis was placed not only on 
the development of precise definitions to facilitate a better understanding between investigators, but 
also on the importance of systematic serial biopsies as a driver for translational research and the 
need for the recording and reporting of data, to facilitate a better understanding of the key processes 
involved.  
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Introduction 
The first evidence of successful cancer immunotherapy (IT) was reported at the end of the 19
th
 
century following intratumoral injections of pro-inflammatory bacterial extracts [1]. More recently, there 
has been a resurgence of interest in cancer IT with the success of immune checkpoint-targeted 
monoclonal antibodies (ICT mAbs), directed against programmed death (PD) receptor 1 (PD-1), PD 
ligand 1 (PD-L1) and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), at improving clinical 
outcomes across a wide range of cancers. However, whilst ICT mAb therapies are limited by the small 
number of patients who achieve an objective response, their systemic immune-related toxicities 
(especially when used in combination), their cost, and the need to overcome IT resistance, are 
currently encouraging the exploration of other IT modalities. Intratumoral IT, as defined by direct 
injection of immunostimulatory agents into the tumor itself, could result in superior priming of the anti-
tumor response. Furthermore, direct injection into the tumor could not only reduce systemic exposure, 
off-target toxicities and the amounts of drug used, but also induce stronger anti-tumor activity in the 
injected tumor lesion and maybe in distant non-injected tumor lesions [2-6]. Also, as described 
previously [2], a significant amount of preclinical rationale supports the concept that some intratumoral 
IT strategies may overcome resistance to ICT mAb monotherapies by priming T cells and/or allowing 
their intratumoral homing function. Thus, it should be stressed that these approaches although acting 
locally, may also help to identify systemic immune effects against cancer. 
 
In principle, intratumoral injections can be considered for any tumor where the primary lesion or its 
metastases are accessible either percuteanously via direct injection or via specific procedures such 
as colonoscopy, cystoscopy, bronchoscopy, thoracoscopy, coelioscopy, or even surgery [7]. There is 
now a plethora of agents being investigated for their role in intratumoral IT, including immune receptor 
agonists (such as Toll-like receptor [TLR] agonists, and STimulator of INterferon Genes [STING] 
agonists), ICT mAbs, wild-type and genetically-modified oncolytic agents (such as viruses and 
peptides), cytokines and immune cells directed at a variety of potential targets [2, 8-10]. Thus, to 
support the clinical development of human intratumoral IT (HIT-IT) strategies, an expert meeting, 
comprising 11 academic experts and 11 pharmaceutical industry experts, together with two clinicians 
representing ESMO (the President and the Chief Medical Officer of ESMO), was convened on 08 
March 2018 in Paris immediately following the ESMO Targeted Anticancer Therapies 2018 
conference.  
 
Aim 
The aim of the meeting was to provide guidance and to help to structure the ongoing and future 
development of HIT-IT. More specifically, the objectives of this academia/industry collaborative effort 
were to harmonize the definitions and terms used, the methodologies, the collection of data and the 
reporting of results by academia and industry within their HIT-IT clinical trials. There was no 
discussion of particular molecules or specific trials during this meeting. 
 
Scope 
The meeting focussed exclusively on the intratumoral* injection of immunostimulatory agents. 
Although, some local physical and radiation strategies with known pro-inflammatory properties can be 
considered to act as local immunotherapies (e.g. cryotherapy, high-intensity focussed ultrasound 
[HIFU] and irradiation by brachytherapy/teletherapy) these strategies were considered to be outside 
the scope of the meeting.  
 
*Foot note  
Some strategies sometimes described as “intranodal” involve the injection of lymph nodes in the lymphoid 
territory draining a tumor lesion. The focus of the present work has been on intratumoral injections, with the belief 
that this is the best way to ensure that immunotherapies will actually reach the tumor draining lymph nodes. 
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Methods 
 
Composition of the expert panel and aims  
 
The 22 international experts were selected on the basis of their demonstrable knowledge of the field 
from either an academic (n=11) or pharmaceutical industry (n=11) perspective. 
 
The aim of this ESMO-sponsored collaboration was to provide tools to help the clinical development 
of HIT-IT strategies by,  
i) Harmonizing the definitions, terms and methods used for HIT-IT clinical trials 
ii) Harmonizing the collection of data, notably the assessment of responses, during HIT-IT 
clinical trials, and standardizing the reporting and evaluation of HIT-IT clinical trial results. 
iii) Emphasizing the importance of collecting serial biopsy and biological specimens as a 
driver of translational research.  
 
Process of consensus 
 
A draft document was prepared and circulated to the 22 experts and two ESMO representatives prior 
to the expert meeting. Based on the available literature and their own personal expertise and 
experience, the international experts were asked at the face to face meeting in Paris to endorse a 
series of definitions, assumptions, and proposals, and finally, to deliver a set of recommendations to 
support the design and management of HIT-IT trials in the future.  
 
Results/meeting outcomes 
 
The resulting output of this effort is the present reference document, which can be used by clinical 
investigators, pharmaceutical companies, ethics committees, independent review boards (IRBs), 
patient advocates, grant-funding organizations and the regulatory agencies to facilitate i) an increase 
in the quality and number of pharmaceutical industry- and academia-sponsored HIT-IT clinical trials, 
ii) a better assessment of HIT-IT trials leading to their approval by regulatory agencies, and finally, in 
the longer term, iii) the implementation of HIT-IT in the standard treatment of many cancers. 
 
Definitions 
 
A list of definitions was established, as outlined below, to help standardize the terminology used and 
facilitate a better understanding amongst those involved in this field of clinical research. 
 
i) HIT-IT: Human IntraTumoral ImmunoTherapy.  
ii) Adaptive immune response: An immune response involving antigen-specific T cells 
(including regulatory T cells [Tregs]) and B cells with memory features.  
iii) Innate immune response: A stereotypic immune response from innate immune cells from 
both the myeloid lineage (such as granulocytes, eosinophils, neutrophils or 
monocytes/macrophages) and the lymphoid lineage (gamma/delta T cells, natural killer 
[NK] cells and NKT cells). In the context of solid tumors, these are predominantly 
represented by myeloid cells (there are few NK cells in the majority of solid tumors).  
iv) Anti-tumor immune priming involves a de novo immune response, i.e. the generation of a 
novel, antigen-specific, adaptive immune response (through either B or T cells or both). 
v) Anti-tumor immune boosting involves the enhancement of a pre-existing immune 
response against the tumor. This terminology can refer to i) the recall effect of a recent 
immune priming event or ii) the disinhibition of a pre-existing anti-tumor immune response. 
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vi) In situ immunization and in situ vaccination are alternative terms used to describe the 
strategy of intratumoral IT aimed at immune priming and/or boosting against the tumor. It 
should be noted that the term “in situ vaccination” could be confusing as it can be used for 
both actual intratumoral injections of a cancer vaccine as well as for intratumoral injections 
with immunostimulatory agents. Also, vaccination is widely understood to be a prophylactic 
rather than a therapeutic intervention. As such, we recommend that in situ immunization 
should be the preferred term. 
vii) Abscopal effects: the term “abscopal” (‘ab’ - away from, ‘scopus’ - target) was proposed in 
1953 to refer to the effects of ionizing radiation “at a distance from the irradiated volume but 
within the same organism” [11]. It is now commonly used to describe the biological or 
anatomical effects (such as objective radiological tumor responses) of radiotherapy outside 
of the field of irradiation. There was a consensus amongst the experts that the term 
“abscopal” was not appropriate for the description of HIT-IT in non-injected lesions. 
“Abscopal” is historically connoted with radiotherapy, which has specific biological effects 
related to its different processes in locoregional tissues and lymph nodes (e.g. multiple 
beam intensity-modulated radiation therapy [IMRT] can affect tissues beyond the strict 
tumor locus). Also, many trials are currently assessing combinations of local IT together 
with systemic treatments where the non-injected sites are exposed to such therapy (e.g 
anti-PD-L1). Therefore, we propose the novel terminology “enestic” versus “non-enestic 
(anenestic)” to define “injected” versus “non-injected” tumor lesions, respectively. 
viii) Enestic tumor lesions: enestic (from “énesi” which means “injection” in Greek) was the 
term proposed to designate tumor lesions that have undergone intratumoral injections. 
Alternatively, the terminology “injected lesions” could be used. 
ix) Non-enestic (or anenestic) tumor lesions are non-injected tumor lesions. 
x) Anenestic immune responses are immune changes seen in non-injected lesions either 
regional or distant. 
xi) Anenestic tumor responses are objective tumor responses as assessed by imaging 
criteria in regional and distant non-injected lesions 
xii) Tumor antigens: includes both Tumor-Specific Antigens (TSA), which are only expressed 
by tumor cells (e.g. neo-epitopes which arise from somatic mutations) and not on any other 
cell, and Tumor-Associated Antigens (TAA), which are preferentially expressed by tumor 
cells but are also found on some normal cells (e.g. carcinoembryonic antigen [CEA]). 
 
Rationale for the use of HIT- IT 
 
HIT-IT addresses some of the limitations of the IT strategies associated with the ICT mAb therapies 
mentioned above, in terms of safety, bioavailability, immune priming, and achieving local effective 
exposure.  
 
Safety  
Intratumoral IT should minimize systemic off-target immune-related adverse events (irAEs), allowing 
the use of safe, synergistic combinations of immunotherapies. 
 
Local Exposure / Bioavailability  
Based on the expectation that locally-injected agents will reach high local concentrations in the 
injected tumor lesion, intratumoral IT offers the opportunity to increase the therapeutic index of 
bioactive agents injected directly into the target whilst achieving low systemic exposure. Intratumoral 
IT allows for an on-target therapeutic window. In addition, direct injection into the tumor may also 
produce a high local concentration of chemokines that helps to recruit the appropriate immune cells 
into the tumor micro-environment to mount an anti-tumor response. 
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Simplicity 
In contrast to personalized vaccination strategies, intratumoral injections of immunostimulatory 
products provide a universally applicable tumor antigen agnostic strategy which allows the immune 
system to react against the most immunogenic of the full repertoire of tumor antigens, without the 
need for the operator to pre-determine which antigens are expressed by the tumor [12]. 
 
Types of HIT-IT 
 
The general opinion was that every immunostimulatory medicinal agent has the potential to be 
injected locally as part of a HIT-IT strategy. These include the following non-exhaustive list of agents: 
 Pattern recognition receptor agonists (PRRs): e.g TLR agonists, STING agonists, RIG-1-
like receptor (RLR) agonists [13] 
 Oncolytic viruses and peptides: e.g herpes, vaccinia, coxsackie, adeno- and reo- viruses, 
and lactoferrin-derived peptides [12, 14-19] 
 Immune checkpoint-targeted antibodies: e.g tumor necrosis factor receptor superfamily 
(TNFRSF) agonists (e.g.OX40, CD137, GITR, CD40) [20], and Ig superfamily/B7.1 
antagonists (e.g. the CTLA-4, LAG-3, TIM-3 and PD-1 immune checkpoints) [8, 21, 22] 
 Cytokines: e.g IL-2, interferons, granulocyte-macrophage colony-stimulating factor (GM-
CSF) [2, 8] 
 Immunometabolic modulators: e.g indoleamine dioxygenase inhibitors, adenosine receptor 
(A2AR) inhibitors, anti-CD73 [2, 8]  
 Encoding nucleic acid sequences: e.g cytokine encoding mRNA [2, 8] 
 Immune system cells: e.g dendritic cells, chimeric antigen receptor (CAR)-T cells, [2, 8]  
 Nano or microparticles [2, 8] 
 Bispecific T-cell engaging antibodies [2, 8]. 
 
Pharmacokinetic evaluation of HIT- IT 
 
Pharmacokinetic (PK) data remain essential for HIT-IT strategies, particularly for novel agents in order 
to establish not only the systemic exposure to, and the half-life of, the agent, but also to build a case 
for its safety. 
 
It can be envisaged that the PK of the agents involved in HIT-IT procedures may be impacted by the 
tumor vasculature, the ratio between tumor size and the volume of injection, tumor interstitial 
pressure, the volume and concentration of the agent, the level of expression of the agent’s target in 
the tumor, the reversibility of binding of the agent to its target (off rate) or to other intratumoral 
molecules (e.g. potential slow release if partially liposoluble), and any local metabolism of the IT 
agent. The PK may also be impacted by features of the host such as anti-drug antibodies and anti-
agent cellular responses (e.g. phagocytosis of oncolytic viruses). 
 
Thus, any PK analysis of HIT-IT trials should include time points that are very close to the time of the 
IT injection as well as those that allow assessment of long-term exposure over the subsequent hours 
and days. Also, the number of patients tested needs to be significant in order to properly assess the 
potential inter-individual variability. To monitor the systemic PK of any locally injected agent, it will also 
be necessary to demonstrate that the effects on non-injected/anenestic tumor lesions are not due to 
any significant systemic exposure to the agent. In addition, tissue PK analyses should be performed 
whenever possible (e.g. neo-adjuvant/window of opportunity settings) in order to establish data on the 
local concentration, the volume of distribution and time on target, of the injected agent. 
 
It should be noted that traditional pharmacokinetic studies investigating absorption, distribution, 
metabolism, elimination, and drug-drug interactions are not relevant in the evaluation of intratumoral 
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oncolytic virus therapies. Non-clinical studies have instead focused on the biodistribution and 
clearance, shedding, and replication in normal and tumor-bearing mice. 
 
 
Pharmacodynamic evaluation of HIT-IT 
 
The development of pharmacodynamic (PD) endpoints will be critical for the development of HIT-IT, 
especially the identification of biomarkers that will allow us to correlate local activity with systemic 
efficacy. Depending on the drugs used, these could include (non-exhaustive list): 
 Treg depletion/modulation 
 Recruitment, activation and/or expansion of anti-tumor T cells (T-cell priming) 
 Activation of anti-tumor B cells (B-cell priming) and generation of tumor-targeting antibodies 
 Recruitment and presentation of antigen presenting cells (APCs): Dendritic cells (DCs), 
macrophages, B cells, and also human leukocyte antigen (HLA)-I and/or HLA-II expression by 
tumor cells 
 Macrophage depletion versus activation or M1/M2 differentiation 
 Enhancement of the antigen-presenting properties of cancer cells (HLA, co-stimulatory/co-
inhibitory molecules) 
 Increased cross-priming of tumor antigens (TSA and TAA) in the tumor microenvironment or 
tumor draining lymph nodes. 
 Emergence of new T-cell receptor (TCR) clones as a measure, albeit non-specific, of an 
expanding repertoire post-treatment 
 Generation of specific circulating immune cells (e.g. proliferation of CD8 + PD1 high T cells) 
 Generation of memory T- and/or B-cell responses 
 Development of tertiary lymphoid structures in tumors 
 Expression of adhesion molecules by endothelial cells 
 Tumoricidal effects 
 Local/distant impact on the patient microbiome. 
 
Going forward, PD studies should be built on the collection of systematic pre-treatment and on- or 
post-treatment biopsies of both enestic and anenestic tumor lesions. Early biopsy time points (i.e. 
prior to the first disease assessment) in both responders and non-responders should be considered 
including those who had documented disease progression (who often do not undergo tumor biopsies 
when disease progression has been clinically or radiologically documented). Currently, the ideal time 
points and targets for PD sampling are unknown but will most probably be dependent on the 
mechanisms of action of the agents or drugs used. As with PK, we recommend that HIT-IT study 
design, as best practice, should also include the analysis of systemic PD target effects at the same 
sampling time points as the tumor biopsies. The timepoints for PD sampling should rely on pre-clinical 
data or be based on their anticipated immune modulatory effects. Repeated PD sampling might be 
necessary during the early stages of development to assess the kinetics and amplitude of the immune 
responses, and also any bell-shaped curve effects due to physiological negative feedback loops. 
 
Intratumoral injections also offer the opportunity to perform longitudinal studies with a tumor biopsy or 
fine needle aspirate (FNA) taken during every intratumoral procedure, and repeated at progression or 
during response. In addition, neoadjuvant, window-of-opportunity designs offer the possibility of 
generating data on the local impact (i.e. surgical specimen and sentinel lymph nodes) of HIT-IT. The 
safety and very low systemic exposure of some HIT-IT strategies may allow us to classify trials of 
intratumoral injections as phase 0 clinical trials.   
 
The prerequisites for the translation of the local immune reaction into efficient systemic anti-tumor 
immunity are still not fully understood. Thus, tumor biopsies are critical to our better understanding of 
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the in vivo PD of immunotherapies. It is recommended that quality checks become part of the 
standard operating procedures for tumor biopsies (e.g confirmation of the actual presence of tumor 
cells in a target lesion at baseline). Clinical trial case report forms (CRFs) should be used to collect all 
the details relating to the biopsied sites. Indeed, the interpretation of translational studies might be 
impacted by the microenvironment of the tissue where the cancer is located. Therefore, it is 
recommended that the locations of all biopsies should be captured on the patients’ CRFs (e.g. lymph 
node versus muscle versus liver). 
 
It was also recommended that pre-treatment tumor biopsies should be performed during the trial 
screening period, and not at the time of the first intratumoral injection, in order to better distinguish 
procedure-related adverse events (AEs) from treatment-related AEs. However, for longitudinal 
studies, tumor biopsies could be performed alongside intratumoral injections.  
 
 
PD studies and the resolution of some unsolved questions 
 
In particular, there is an urgent need to generate data regarding the generation of a systemic immune 
response. The unsolved questions include:  
 Are pre-existing immune infiltrates (and their phenotype) predictive of the efficacy of HIT-IT? 
 Are there specific combinations of HIT-IT which could prime/enhance anti-tumor immunity? 
 Is the quality (i.e. phenotype) of the tumor immune infiltrate more important than their 
topography (i.e. location in the tumor) or are they both important? 
 Are some tumor histiotypes or tumor sites/subsites more sensitive to HIT-IT? 
 Are there primary mechanisms of resistance which prevent patients from responding to HIT-
IT? 
 Does HIT-IT deliver drugs better to, or have more impact on, tumor draining lymph nodes 
than systemic treatment?  
 Are some tumor histotypes and tumor sites better than others to prime an anti-tumor immune 
response against non-injected sites? 
 Are some tumor histotypes and tumor sites better than others to generate an objective 
radiological tumor response in non-injected sites? 
 Can HIT-IT change a cold (non-inflamed) tumor into a hot (inflamed) tumor? 
 Are typical biomarkers associated with systemic IT efficacy also correlated with the efficacy of 
HIT-IT (e.g. PD-L1 expression or tumor mutational burden)? 
 Does HIT-IT require combination with systemic treatment (e.g. ICT mAbs)? 
 
Clinical Goals of HIT-IT 
 
The clinical aims of HIT-IT depend on the type of clinical trials (Phase 1, 2 or 3), and include the 
achievement of: 
 Local efficacy, i.e. an objective response at the site of injection (target tumor site), with special 
interest in the ability to generate enestic (local) complete responses, is of relevance especially 
for tumors that are invading into adjacent vital structures such as is seen in head and neck 
squamous cell carcinomas 
 Systemic efficacy as evidenced by anenestic responses, including a clear definition and 
demonstration of the occurrence of such activity (to be discussed further below) 
 “Drug escalation” at the site of injection rather than dose escalation (i.e. an increase in the 
number of locally-delivered drugs with the aim of seeking synergistic combinations rather than 
searching for an optimal dose) 
 Reversal of resistance (intrinsic primary resistance and adaptive or acquired secondary 
resistance) 
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 The treatment of sanctuary sites (where it is difficult to get a sufficient concentration of 
chemotherapy or infiltration of immune cells; e.g. bone and ovaries, respectively), or sites of 
oligoprogressive disease, as part of a more generalized response 
 The provision of symptom relief 
 Down-sizing and reducing the recurrence of tumors in the neo-adjuvant setting. 
 
The unresolved clinical questions of HIT-IT 
 
In achieving these clinical aims, there are many important questions that remain to be further explored 
and resolved. These are as follows: 
 Does injecting a metastasis versus a primary tumor influence the efficacy of HIT-IT? 
 What are the limiting factors in the achievement of a distant anenestic response? Is this 
dependent on soluble factors, the homing of T cells, local T regs or the presence of 
macrophages, or other APCs? 
 Is the concomitant injection of numerous tumor lesions better than the sequential injection of 
an increasing number of tumor lesions over time, in order to target as many sources of 
antigenic diversity as possible and generate true polyclonality of the anti-tumor response? 
 How do the treating physicians prioritize which tumor lesions to inject if only a limited 
volume/dose can be administered at each treatment visit? Should prioritization be made 
according to tumor size, beginning with the largest lesion, or alternatively involve the injection 
of any new injectable lesion that has appeared since the previous injection? 
 Does the sequential injection of multiple tumor lesions generate a priming or boosting effect? 
 Does neo-adjuvant HIT-IT protect against post-surgical relapses? 
 Does HIT-IT generate a better memory anti-tumor immune response than systemically 
administered immune therapies? 
 How long do we need to continue to inject locally? How do we decide when to stop?  
 When an injected tumor lesion achieves a complete response (CR), should we inject other 
non-injected lesions? 
 Should concomitant lymphadenectomy be performed or is lymphadenectomy harmful for the 
long-term effect of HIT-IT (e.g. neo-adjuvant settings)? 
 Can more than one HIT-IT agent be co-injected in the same lesion achieving synergistic 
efficacy?  
 
Long term (>6 month) radiologically stable disease might sometimes be explained by scars secondary 
to histological necrosis. Thus, we recommend biopsying tumor lesions which become durably stable 
upon HIT-IT in order to document the ongoing biological changes (including potential necrosis) and to 
inform our understanding of the overall biological processes involved in injected and non-injected 
lesions. We also recommend biopsying tumor lesions showing dissociated (mixed) responses, or new 
tumor lesions, in the context of overall disease control, for the same reason. 
 
Intratumoral injections and injectability  
 
Several parameters can impact the development of HIT-IT as a therapeutic strategy such as the 
choice and size of the target tumor lesion, the accessibility of that lesion, the conspicuity of that lesion 
and the availability of the appropriate imaging techniques to properly inject/assess those lesions. 
 
Tumor site and location 
The experts presented their opinions on tumor site and location as follows. All tumor sites are 
potentially injectable, but injection at some tumor sites might require the support of additional 
clinical/surgical/radiological specialities and specific technologies in order to achieve accurate 
injection of the target lesion. These include the use of ultrasound, computed tomography (CT)- and 
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magnetic resonance imaging (MRI)-guided injections, colonoscopy, cystoscopy, bronchoscopy, 
thoracoscopy, coelioscopy, and surgery. 
 
Some visible or palpable tumor lesions, depending on their location, can be injected without image 
guidance. Indeed, within current clinical practice using approved intratumoral compounds, local 
treatment of superficial lesions does not require any specific image guidance:  
 Skin and sub-cutaneous lesions 
 Superficial lymph nodes (e.g. inguinal, sub/supraclavicular, cervical) 
 Mucosal  lesions (e.g. oral, anal, cervical), 
 
There are tumor lesions that, depending on their location, will require imaging guidance in order to be 
injected for example: 
 Lung lesions  
 Liver lesions 
 Deep (e.g. retroperitoneal, pelvic, thoracic) lymph nodes. 
 
Tumor lesions, at specific locations, could require endoscopic guidance in order to be injected. Such 
lesions include: 
 Endobronchial lesions (e.g. non-small cell lung cancer) 
 Endoluminal lesions (e.g. colorectal cancer) 
 Endosinusal lesions (e.g. head and neck squamous cell carcinoma). 
 
Also, it should be noted that some tumor lesions can only be accessed via surgical procedures, for 
example most peritoneal lesions and central nervous system tumors. As a consequence, these 
lesions cannot undergo multiple local injections unless a means of inserting a delivery port at surgery 
can be safely defined. 
 
Most superficial tumor lesions (cutaneous, subcutaneous and superficial lymph nodes) can be 
injected under ultrasound guidance. Accessible liver metastases can also be injected using ultrasound 
guidance. Within clinical trials, ultrasound guidance is recommended not only to guide the positioning 
of the needle in the tumor lesion, but to allow for tumor measurements (tumor dimensions) at every 
injection in order to better monitor the kinetics of response/progression and local tissue changes (e.g. 
necrosis or hematoma). However, this recommendation does not apply to post-approval routine 
practice when lesions can be visually injected. Doppler ultrasound is recommended for injections with 
agents where there is a potential risk of systemic exposure, to ensure that the injection is not 
performed within a vessel. 
 
Ultrasound-guided injections of deep tumor lesions should be offered to patients whenever the 
procedure seems feasible, in order to avoid the burden of CT-guided procedures (i.e. repeated X-ray 
exposure and longer procedures). However, CT is mandatory for the injection of lung tumor lesions. 
 
Tumor size limits  
Within clinical trials, injected tumor sites should measure ≥1 cm in diameter (≥1.5 cm for lymph nodes) 
to ensure injectability. For skin and subcutaneous lesions where confidence in achieving intralesional 
delivery is higher, smaller diameters might be eligible. Within clinical practice for approved 
compounds, there might be no tumor size limits, most notably for the local treatment of superficial 
tumor lesions.  
 
Image-guidance 
Image-guidance essentially involves three different steps, guidance of the needle, assessment of the 
needle’s location prior to delivery, and the post-injection assessment of drug delivery. 
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Guidance of the needle is a relatively standard procedure and can be left to the operator. The 
assessment of the position of the needle can be captured and monitored (using screen shots) during 
standard radiological procedures (ultrasound- or CT-guidance). The needle position should be 
specified (e.g. central, peripheral or peritumoral) and may involve multiple positions during the same 
procedure (e.g. clockwise in the tumor at positions 12, 3, 6, and 9 o’clock, or similar to local 
anesthesia using one injection to apply multiple depots in a prespecified confined area). Finally, a 
rigorous assessment of drug delivery requires that the drug can be seen with standard imaging 
techniques or co-injected with a radio-opaque product and then monitored. Such studies have shown 
that the distribution of drugs in a tumor lesion can be highly non-homogeneous [23-27]. However, 
some HIT-IT agents might be affected by radio-opaque products which could make such co-injection 
detrimental.  
 
CT scan image capture allows for external review, which ultrasound does not. Both techniques allow 
for the acquisition of 3D volume data. Factors associated with the success of image-guided needle 
biopsies of tumors have been published elsewhere [28].  
 
Expertise in interventional radiology, contrast-enhanced ultrasound and CT-scan availability for the 
procedures described above, are all practical considerations for selecting centers for HIT-IT clinical 
trials. 
 
Needle size and length  
Needles are available in a range of lengths and gauges (diameters) for the delivery of drugs, 
vaccines, and other substances. For intratumoral injections involving a deep lesion a 22 gauge (0
.
72 
mm) needle should be used (as a thinner needle is difficult to manipulate in deeper lesions), but for 
skin lesions, needles as small as 30 gauge (0
.
31 mm) may be used [28]. For tumor biopsies, an 18 
gauge needle (1
.
27 mm) is recommended, with the collection of up to 6 cores possible per procedure. 
 
Syringes 
Only Luer lock syringes should be used in order to avoid leakage and accidental dislodgement of the 
needle during intratumoral injections. No specific needle or device has currently demonstrated its 
superiority in terms of therapeutic efficacy or pain relief. 
 
Volumes of injections 
For skin and mucosal lesions, depending on the volume of injection (e.g. >200uL), increased 
interstitial pressure and tumor size can increase the risk of extravasation (back spilling), resulting in 
less control over the actual local delivery of the agent. In general, for deep lesions, a minimum volume 
of 500uL is recommended to ensure better control of the delivery. Every intratumoral procedure and 
pharmacy preparation should take into account the dead space of the needle to ensure that the actual 
prescribed dose is delivered to the target lesion(s).  
 
Number of lesions injected 
Multiple lesions can be injected during the same procedure. This could involve the same needle being 
used for multiple site injections within the same patient, which would prevent syringe manipulation, 
drug spillage and drug exposure to the patient and the operator during the injection procedure. 
Alternatively, one syringe/needle could be prepared for each lesion to be injected. 
 
Operators 
Any trained nurse, doctor, radiologist, interventional radiologist or surgeon can perform intratumoral 
injections. 
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Procedures 
 
Local (at site of injection) plus or minus systemic analgesic treatments should be anticipated and 
initiated at least 30 minutes prior to any painful HIT-IT procedure. Skin analgesia at the site of 
injection can be administered using topical xylocain (4%) or other local anaesthetic agents. The 
options for systemic analgesia should include the full range of analgesia from 
paracetamol/acetaminophen to opioids, depending on the precise details of the procedure and the 
patient’s underlying symptoms. Preference should be given to the use of the thinnest needle available 
to minimise morbidity and limit leaks from multiple punctures. Ideally if multiple parts of the same 
lesion need to be injected, a single puncture entry point to the tumor lesion is preferred. For large 
lesions, intratumoral injections should be preferentially targeted towards viable tissue near the 
periphery of the tumor, and should not be injected into the necrotic core. Also, for tumor lesions that 
are too dense or hard to penetrate with a needle, injections should be delivered around the periphery 
of the lesion. As mentioned above, a fan-shape injection technique should allow better diffusion 
of/exposure to the injected product in the tumor lesion. However, research is needed to optimize the 
tools for delivering local IT. The added value of a needle with multiple side-holes or a multi-pronged 
needle remains to be demonstrated. 
 
As the impact of the needle trauma on the tumor immune microenvironment is unknown, sham 
procedure studies (e.g. an intratumoral injection of saline) are needed to evaluate any potential 
impact. Similarly, the impact of local/systemic anesthetics on immune cells in vivo, or on the stability 
of the injected agent, also remain largely unknown. 
 
Patient exclusion criteria 
 
Use of anti-coagulant agents or history of significant bleeding diathesis  
Patients on agents such as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or clopidogrel are 
eligible to receive HIT-IT and these agents do not have to be withheld. For procedures with moderate 
or significant risk of bleeding (deep lesions and/or organs), long-acting agents such as aspirin or 
clopidogrel should be discussed on a case by case basis (tumor board, principal investigator, medical 
monitor, or standing policies of the IR group). Patients with therapeutic doses of anticoagulants, 
should be excluded from most deep lesion biopsies and injections. However, for deep injections in 
patients receiving a preventive dose of low molecular weight (LMW) heparin it is recommended that 
their LMW heparin treatment is stopped 24 hours prior to the intratumoral injection and resumed again 
24 hours after the injection. A minimum platelet count of 50,000/mm
3
 is recommended for patients 
being injected in deep tumor lesions. No specific coagulation and platelet restrictions should be 
applied to patients with skin, sub-cutaneous and superficial lesions where mechanical hemostasis can 
be easily implemented. 
 
History of severe allergy to the injected agents 
Patients with a known severe allergy (Common Terminology Criteria for Adverse Events [CTCAE] 
grade 3-4) to the injected agents should be excluded from such a therapeutic strategy. This exclusion 
should only concern patients who have experienced actual anaphylactic reactions (i.e. IgE-mediated 
events). Patients with a history of anaphylactoid reactions (i.e. mastocyte degranulation) are not 
excluded but it is suggested that such patients should be treated with caution and, perhaps, a more 
prolonged period of observation in the hospital setting after the first 1-3 injections. 
 
Risk of vascular catastrophe 
Lesions in the vicinity of large vessels with a risk of vessel blow out (e.g. the common, internal or 
external carotid arteries or their branches), or other situations with a risk of vascular catastrophe such 
as tumor-encased large vessels should be excluded from HIT-IT. Notably, special caution should be 
taken in patients with neck lesions that have been re-irradiated, especially if the second course of 
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radiation was given at radical doses with curative intent, and in whom the disease is ulcerated and/or 
connects to a skin or mucosal surface. Also, patients with tumor lesions with macroscopic 
intravascular tumor invasion (e.g. liver lesions with tumor infiltration into the main portal vein, hepatic 
vein or vena cava) should not receive intratumoral therapy. 
 
Dose/regimen 
 
Rationale for the choice  
Typical de novo immune reactions, against pathogens/vaccines for example, include a priming phase 
with intense immediate, stereotypic, innate immune activation for several days in a row followed by 
the generation of a slower, antigen-specific, adaptive, T cell- and B cell-mediated, immune response. 
This step can be associated with fever, which is a physiological sign of the systemic immune reaction 
whose intrinsic features and properties contribute to the efficacy of the immune reaction. Therefore, 
fever per se should not be treated or prevented unless it is not well tolerated by the patient (e.g. 
elderly patients). If necessary, patients can receive antipyretic medications, such as 
paracetamol/acetaminophen, and nonsteroidal anti-inflammatory drugs such as naproxen, diclofenac, 
or ibuprofen. Subsequent re-exposures to the same antigens have fewer systemic effects and mostly 
rely on the adaptive immune system. Every re-exposure to the antigen results in an enhancement of 
the adaptive immune response against the antigen (i.e. as a boosting effect). 
 
The ideal dose or regimen for HIT-IT has not yet been determined for any immunostimulatory agent 
and is expected to vary across agents depending on their mechanisms of action and their local PK/PD 
properties.  
 
The conventional rules for drug development such as identifying dose-limiting toxicities (DLTs) and 
maximum tolerated dose (MTD) might not be appropriate for HIT-IT trials. Instead, beyond safety 
assessment, phase 1 HIT-IT clinical trials are needed to determine the optimal active dose/regimen 
with either specific biomarkers or early radiological assessments. Also, the every 2-week and every 3-
week regimen/cycles inherited from systemic chemotherapy trials as a strategy for managing the 
cyclical toxicity of cytotoxic agents, are not relevant for immunostimulatory agents. Thus, HIT-IT trials 
with innovative regimen and schedule designs are to be encouraged. 
 
Dose per injection 
Doses per injection timepoints can be determined on a per lesion basis (fixed dose/volume or adapted 
to the size of lesions), on a tumor load basis or on a per patient basis (fixed dose per patient versus 
per body weight dose). Which dosing paradigm to pursue might depend on the predominant toxicity of 
the IT agent. For example, a dose per lesion (i.e. fixed concentration) approach might be more 
appropriate if injection-site reactions are dose-limiting, whilst a dose per patient (i.e. fixed total dose) 
approach would be more suitable if systemic toxicity prevails. The ratio between the volume of 
injection and the injected lesion/tumor size may be critical for the activity of the HIT-IT. Therefore, the 
details of the size of the injected lesions and the actual injected volume of the IT agent should be 
collected during clinical trials on the CRFs.  
 
Priming  
Depending on the local half-life and/or the duration of the local bioactivity of the immunostimulatory 
agents, several intratumoral injections might be necessary for the local priming of the anti-tumor 
immune response. Therefore, a certain dose-intensity might be useful during this initial induction 
phase. However, some tumor sites might be less amenable to multiple injections. The minimal 
number of injections, per tumor lesion, needed to obtain priming remains undetermined. Also, it is not 
known if the initial injection of multiple lesions generates a better priming response than the injection 
of a single lesion. Evaluation of these parameters in early-phase clinical trials is encouraged, since 
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this knowledge may allow the more rational application of a specific HIT-IT agent – and may 
contribute to a general understanding in the field. 
 
Boosting  
Based on the experience of adaptive immune responses against pathogens and anti-infectious 
vaccines, repeated intratumoral injections at least 3 weeks apart might enhance the adaptive 
immunity against the tumor. The minimal number of injections needed to achieve boosting also 
remains undetermined. 
 
Prime-boosting  
A prime-boosting effect could be achieved by injecting multiple tumor lesions over time, or by 
modifying the type of agent used for HIT-IT (e.g. two different oncolytic viruses). 
 
Dose escalation versus drug escalation  
 
During conventional drug development, a classical dose-escalation trial design aims to identify the 
MTD of an investigational agent based on the incidence of DLTs, in order to develop the agent further 
at the recommended phase 2 dose (RP2D). During intratumoral IT, high concentrations of 
immunostimulatory agents can easily be reached in the absence of systemic toxicities, and, therefore, 
without DLTs. Therefore, the aim is to identify an optimal bioactive dose which, together with the low 
level of systemic toxicity, allows for a drug-escalation rather than a dose-escalation trial design. In 
other words, the focus is no longer on defining the safety of a systemic monotherapy dose escalation 
but rather to study the safety of local combinations of immunostimulatory agents, each being tested at 
a flat optimal bioactive dose. 
 
Lesion escalation versus dose-intensity escalation 
 
In order to better address the heterogeneity of cancer, one HIT-IT strategy could consist of injecting 
as many tumor lesions as possible to prime the anti-tumor immunity against as many neo-antigens as 
possible. Ideally, once the RP2D of a HIT-IT agent has been defined, subsequent development would 
include small-scale, randomized, comparison of single- versus multiple-lesion approaches, with the 
specific goal of defining the optimal biological effects of therapy.   
 
Dose-limiting toxicities (DLTs)  
 
Although the level of inter-individual variability is high with biotherapies, the current design of first in 
human trials aims to have clear, dose-related, expected toxicities usually within a timeframe of 3 to 4 
weeks (DLT period) [29]. However, because local tissue inflammation/damage generated by 
intratumoral IT could be problematic beyond 4 weeks, we recommend that investigators and sponsors 
of HIT-IT trials also take into account adverse events occurring beyond the DLT window (e.g. the 3-
month non-healing rate of superficial injected lesions when determining the RP2D of HIT-IT). 
 
Summary conclusions 
 
Recommendations for HIT-IT trial design 
 
The recommendations of the expert panel for HIT-IT are as follows: 
 
1. The patient population should be carefully selected for clinical trials in order to be able to 
detect clear signs of activity (i.e. patients able to undergo biopsies and with obvious injectable 
and measurable target tumor lesions). 
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2. Translational studies should be conducted systematically to facilitate a better understanding 
of the mechanism of action of the HIT-IT and identify relevant biomarkers of activity.  
3. Face-to-face meetings between interventional radiologists, radiologists and/or surgeons and 
oncologists should be arranged during the screening periods to define and prioritize the 
radiological assessment of injected and non-injected sites. These discussions and their 
conclusions should be documented in the patient file. 
4. Image-guided injections:  
a. Ultrasound guidance is preferred for the injection of superficial tumor lesions to 
ensure the correct positioning of the needle 
b. Ultrasound guidance or alternatively CT-scans should be used to guide the injection 
of deeper tumor lesions 
c. Doppler ultrasound should be used to make sure that no big vessels are injected in 
error, and thus avoid inadvertent systemic drug/agent delivery. 
5. Measurement of injected and non-injected lesions should be performed at each injection time 
point to better capture the kinetics of tumor growth/response. 
6. Diagrams/photographs should be generated at every visit/time point of injection and should 
be recorded on specific body-map proformas. 
 
Reporting of HIT-IT trial data  
 
Metastatic cancers 
The assessment and reporting of the objective response rate (ORR) in injected (enestic) and non-
injected (anenestic) tumor lesions is mandatory for the proper evaluation of the efficacy of HIT-IT 
strategies. The iRECIST criteria, applied separately to injected and non-injected tumor lesions, could 
be used to evaluate the radiological activity of HIT-IT as they take into consideration the atypical types 
of responses that immunotherapies can generate (pseudo-progressions, late responses and mixed 
responses) [30]. However, iRECIST was designed for studying systemic treatments. Conversely, HIT-
IT is unique, as tumor responses in both injected and non-injected lesions could be of clinical 
relevance. It is therefore possible that dedicated tumor response criteria, specific for HIT-IT trials, will 
eventually outperform and replace the current iRECIST criteria. At the clinical trial population level, the 
total number of injected versus non-injected tumor lesions should always be documented when 
providing percentages of responses. Ideally, the median number of injected lesions per patient, the 
median number of anenestic responding tumor lesions per patient and the median number of total 
lesions per patient should be reported. 
 
Waterfall plots of HIT-IT trials should be used to report the iRECIST responses of injected and non-
injected tumor lesions for every patient, as illustrated in Figure 1. The durations of response for both 
injected and non-injected lesions should be reported in 3D waterfall plots [31]. 
 
 RECIST 1.1 should be used for the overall assessment of tumor responses (as for irradiation, 
treated tumor lesions should not be considered as target lesions as per RECIST1. 1). Injected 
and non-injected tumor lesions need to be reported separately. 
 For patients with lymphoma, the assessment of the injected versus non-injected lesions 
should be conducted according to RECIL 17 criteria [32]. 
 Six-month disease control rate (DCR), duration of response, and the survival of responders 
may be used instead of ORR to assess clinical efficacy. 
 RANO criteria for brain lesions are recommended [33, 34]. 
  
Also, the ORR per type of injected lesion should be specified (skin versus subcutaneous versus lymph 
nodes versus liver versus lung versus other organs). 
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When systemic therapies are used in combination with intratumoral IT (e.g. intravenous anti-PD-L1), 
randomization or a strong historical control is required to demonstrate the added value of intratumoral 
IT on the ORR of anenestic lesions. 
 
In order to assess the ability of HIT-IT to address metastatic disease of poor prognosis, the ORR per 
type of anenestic lesion should ideally be reported routinely for the following sites: 
─ ORR of anenestic lung metastases 
─ ORR of anenestic liver metastases 
─ ORR of anenestic brain metastases. 
  
In order to assess the impact of priming sites, the ORR of anenestic lesions per type of enestic 
priming site should ideally be reported routinely for the following sites: 
─ ORR of enestic skin lesion 
─ ORR of enestic lymph node lesion 
─ ORR of enestic liver lesion 
─ ORR of enestic lung lesion. 
 
Local cancers 
Evaluation of the efficacy of a HIT-IT strategy in the localised cancer setting could involve the use of: 
 iRECIST ORR or DCR of injected tumor lesions 
 Pathological complete response (pCR) rate on surgical specimens 
 Relapse-free survival for surgically removed local tumors 
 Progression-free survival for inoperable tumors. 
  
The challenges 
 
The major current challenges for the practical implementation of HIT-IT strategies are as follows: 
 
Injectability  
All tumor sites are potentially injectable, but the injection of some is more complicated than others. 
For example, liver metastases that are not visible without contrast-enhanced imaging may be 
particularly challenging. 
 
Types of injections 
The local trauma generated by the needle might have an impact on the local inflammatory response 
and could be contributing/deleterious to the injected therapy. 
 
Local diffusion 
Depending on the tumor type, the interstitial pressure, the level of intratumoral vascularization and 
necrosis, the local diffusion of injected agents might be non-uniform. 
 
Systemic exposure 
Depending on the nature of the drug used, the reversibility of its binding to its target and the 
vascularization or fat content of the injected tumor lesions, the systemic exposure and PK of the agent 
might also be variable. 
 
Local combinations 
Local combination of immunostimulatory agents raises questions about the stability of the agents 
when mixed together either ex vivo or in vivo. 
 
Figure 2 summarizes for investigators and pharmaceutical companies the important points to consider 
when designing an intratumoral immunotherapy clinical trial. 
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Key message 
 
The authors consolidated their expertise to provide a series of expert opinions which can be used to 
provide guidance to clinical investigators, pharmaceutical companies, ethics committees, independent 
review boards and regulatory agencies when working on or reviewing HIT-IT clinical research, with a 
view to ensuring the collection of meaningful data from such trials.  
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Figure 1. Waterfall plot for HIT-IT trials. Both injected and non-injected lesions should be 
reported for every patient. Patients should be displayed from progressors to responders according to 
the ORR of their non-injected lesions. These data are for the purpose of illustration only and are not 
based on actual clinical data. 
CR, complete response; DR, dissociated response; PR, partial response; SD, stable disease 
 
Figure 2: Points to consider when designing an intratumoral immunotherapy clinical 
trial. ADAs: Anti-Drug Antibodies, PK: Pharmacokinetics; PD: Pharmacodynamics; DLT: Dose-
Limiting Toxicities; MTD: Maximum Tolerated Dose; RP2D: Recommended Phase 2 Dose.
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